Clinical Pipeline Underpins Infrastructure Investment

The Geneva life sciences cluster, based on shared laboratory facilities at Campus Biotech and Superlab Suisse, is reducing the capital expenditure (CapEx) for early-stage companies. This is more than just real estate expansion; it's a Lab-as-a-Service model that reduces the time from candidate discovery to clinical trial material production. In 2024, the Swiss biotech industry generated CHF 7.2 billion in revenue, CHF 2.6 billion in R&D spending, and secured CHF 2.5 billion in funding, supporting the demand for infrastructure.

ATP128 Targets Immunologically 'Cold' Colorectal Cancer

ATP128, an unnamed clinical-stage therapeutic cancer vaccine acquired by Boehringer Ingelheim from AMAL Therapeutics, utilizes the KISIMA protein platform to deliver colorectal cancer-associated antigens to antigen-presenting cells, inducing TLR2/TLR4 signaling and T-cell responses. It is being evaluated in a Phase 1b trial (KISIMA-01, NCT04046445) for patients with stage 4 microsatellite-stable (MSS) and mismatch repair-proficient (pMMR) colorectal cancer, and includes a combination with the PD-1 antibody ezabenlimab (BI 754091) and the VSV-GP128 viral vector. This patient population represents a typical immunologically 'cold' tumor with limited response to checkpoint inhibitors alone, and the commercial value of the vaccine hinges on its ability to actually increase immune cell infiltration. The global market for colorectal cancer therapeutics in 2024 is estimated at $9.7 billion, with FOLFOX/FOLFIRI, bevacizumab, cetuximab (for RAS-mutant tumors), and pembrolizumab (for MSI-H/dMMR patients) as key competitors.

Dencatistat Seeks Differentiation in Hematological Malignancies and Thrombocytopenia

Dencatistat (STP938), an unnamed oral CTPS1 inhibitor from Step Pharma, blocks CTP synthesis, which is necessary for lymphocyte proliferation. NCT05463263, a Phase 1/2 trial for relapsed/refractory B-cell and T-cell lymphomas, is in the recruitment phase, and VECTRA, NCT06786234, a Phase 2 trial for high-risk essential thrombocythemia, is also underway. The market for essential thrombocythemia is estimated at $977 million in 2024 and competes with standard cytoreductive therapies such as hydroxyurea, anagrelide, and pegylated interferon. Rather than FDA/EMA/PMDA approval or review by an Oncologic Drugs Advisory Committee (Odac), demonstrating clinical safety and response rates is key to increasing its value.

Acquisitions and Regional Networks Demonstrate Capital Recovery Pathways

Boehringer Ingelheim acquired AMAL Therapeutics on July 15, 2019, for a total consideration of up to €325 million. The agreement consists of an upfront payment, clinical, development, and regulatory milestone payments, and commercial milestone payments of up to €100 million, with each specific amount defined within the overall limit. Even after the acquisition, AMAL's continued presence in Geneva serves as an anchor, connecting the research, clinical, and CDMO capabilities of the University of Geneva, Geneva University Hospitals, and KBI Biopharma. The investment appeal of the Geneva model lies not only in clinical success but also in the established precedent of platform companies being acquired by global pharmaceutical companies.